移植：尿中的可溶性尿激酶型纤溶酶原激活物受体（suPAR）而非血清中的suPAR可能预测局灶节段性肾小球硬化（FSGS）复发。 - Suppr | 超能文献

Transplantation: Urine--but not serum--suPAR might predict FSGS recurrence.

作者信息

Kelsey Rebecca

出版信息

Nat Rev Nephrol. 2013 Aug;9(8):432. doi: 10.1038/nrneph.2013.117. Epub 2013 Jun 25.

DOI:10.1038/nrneph.2013.117

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Transplantation: Urine--but not serum--suPAR might predict FSGS recurrence.移植：尿中的可溶性尿激酶型纤溶酶原激活物受体（suPAR）而非血清中的suPAR可能预测局灶节段性肾小球硬化（FSGS）复发。

Nat Rev Nephrol. 2013 Aug;9(8):432. doi: 10.1038/nrneph.2013.117. Epub 2013 Jun 25.

2

suPAR and FSGS: the gap between bench and bedside.可溶性尿激酶型纤溶酶原激活物受体与局灶节段性肾小球硬化：基础研究与临床应用之间的差距

Transplantation. 2013 Aug 27;96(4):368-9. doi: 10.1097/TP.0b013e31829e6d40.

3

Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.尿而非血清可溶性尿激酶受体（suPAR）可识别肾移植候选者复发性 FSGS 病例。

Transplantation. 2013 Aug 27;96(4):394-9. doi: 10.1097/TP.0b013e3182977ab1.

4

Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.鉴定原发性局灶节段性肾小球硬化的潜在生物标志物及其与移植后复发的关系。

Clin Transplant. 2019 Mar;33(3):e13487. doi: 10.1111/ctr.13487. Epub 2019 Feb 21.

5

Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.原发性局灶节段性肾小球硬化症患者的尿可溶性尿激酶受体水平升高且具有致病性。

BMC Med. 2014 May 20;12:81. doi: 10.1186/1741-7015-12-81.

6

Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb.使用CytoSorb去除局灶节段性肾小球硬化（FSGS）因子可溶性尿激酶型纤溶酶原激活物受体（suPAR）。

J Clin Apher. 2017 Dec;32(6):444-452. doi: 10.1002/jca.21538. Epub 2017 Mar 29.

7

Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.采用强化血浆置换及可溶性尿激酶型纤溶酶原激活物受体介导的足细胞β3整合素激活同步监测治疗复发性原发性局灶节段性肾小球硬化症

Transplantation. 2015 Dec;99(12):2593-7. doi: 10.1097/TP.0000000000000914.

8

Soluble urokinase receptor and focal segmental glomerulosclerosis.可溶性尿激酶型纤溶酶原激活物受体与局灶节段性肾小球硬化

Curr Opin Nephrol Hypertens. 2012 Jul;21(4):428-32. doi: 10.1097/MNH.0b013e328354a681.

9

Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.循环尿激酶受体是局灶节段性肾小球硬化的病因。

Nat Med. 2011 Jul 31;17(8):952-60. doi: 10.1038/nm.2411.

10

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.肾小球疾病中可溶性尿激酶型纤溶酶原激活物受体的重新评估

Kidney Int. 2015 Mar;87(3):564-74. doi: 10.1038/ki.2014.346. Epub 2014 Oct 29.

引用本文的文献

1

Biomarkers to predict or measure steroid resistance in idiopathic nephrotic syndrome: A systematic review.预测或测量特发性肾病综合征中类固醇抵抗的生物标志物：一项系统综述。

PLoS One. 2025 Feb 13;20(2):e0312232. doi: 10.1371/journal.pone.0312232. eCollection 2025.

本文引用的文献

1

Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.尿而非血清可溶性尿激酶受体（suPAR）可识别肾移植候选者复发性 FSGS 病例。

Transplantation. 2013 Aug 27;96(4):394-9. doi: 10.1097/TP.0b013e3182977ab1.

2

Circulating suPAR in two cohorts of primary FSGS.原发性 FSGS 两队列的循环 suPAR。

J Am Soc Nephrol. 2012 Dec;23(12):2051-9. doi: 10.1681/ASN.2012030302. Epub 2012 Nov 8.